Last reviewed 2026-04-20 · How we verify

Dimetane-Dx (BROMPHENIRAMINE)

Dimetane-Dx (BROMPHENIRAMINE) is a small molecule histamine H1 receptor antagonist developed by and currently owned by various generic manufacturers. It was first approved by the FDA in 1957 for the treatment of allergic conjunctivitis, allergic rhinitis, dermatographic urticaria, influenza-like symptoms, itching of the skin, nasal discharge, seasonal allergic rhinitis, and urticaria. As an off-patent medication, Dimetane-Dx is available from multiple generic manufacturers. Key safety considerations include potential drowsiness and anticholinergic side effects. Dimetane-Dx is a commercial option for patients seeking relief from allergic symptoms.

At a glance

Approved indications

• Allergic conjunctivitis
• Allergic rhinitis
• Dermatographic urticaria
• Influenza-like symptoms
• Itching of skin
• Nasal discharge
• Seasonal allergic rhinitis
• Urticaria
• Vasomotor rhinitis

Common side effects

No common side effects on file.

Key clinical trials

• Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents (PHASE1)
• Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis (PHASE3)
• Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis (PHASE3)
• Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute Rhinitis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Dimetane-Dx CI brief — competitive landscape report
• Dimetane-Dx updates RSS · CI watch RSS